Niagara Falls, NY -- (SBWIRE) -- 01/06/2014 -- New research published in the Journal of Commercial Biotechnology shows that investment in start-up biotech companies outside the USA has essentially disappeared.

"Getting investment is never easy, nor should it be" says Dr. William Bains, lead author on the study, "But since 2007 it has become almost impossible to get European investors to see the value in really visionary technologies. This is why Boston and New York are full of European scientists and entrepreneurs. Luckily, we retain enough imaginative businessmen in Europe to build businesses without the banks and venture capitalists over here. But today's breakthroughs in medicine, renewables, fuels, materials, will be commercialized where there are investors who value the future. If I were a young, entrepreneurial scientist today, I would 'go West'. "

Recent research led by William Bains examines biotechnology venture capital investment patterns for the past 7 years, and shows that a Cambridge-area biotechnology start-up today can expect little venture capital support. Further, the research indicates that companies are adopting financial models based on angel investment, grants and revenue, and moving away from business models that need substantial investment.

Government and research council policy is beginning to recognize and align with the new investment realities, and the study authors believes this trend will accelerate as internet-mediated angel investing, such as crowd-funding schemes seen in other sectors, emerges as a developing force in the next decade.

For more information, see "Funding biotech start-ups in a post-VC world" at http://CommercialBiotechnology.com

For Further Information contact:

Yali Friedman
Phone: 202-888-4440
email: editor@commercialbiotechnology.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

This book has been released to provide information about the regulations, science and laws related to biotechnology business

Niagara Falls, NY -- (SBWIRE) -- 12/05/2013 -- Dr. Yali Friedman, Ph.D., is a former biotechnology management instructor at the graduate school of National Institutes of Health (NIH). He is also the publisher/chief editor of the Journal of Commercial Biotechnology and the founder of thinkBiotech. This well-qualified and experienced personality has recently written a book on biotechnology business called Building Biotechnology.

This informative book is now available for sale in all leading bookshops. Building Biotechnology comprises 20 chapters and 388 pages, primarily focused on covering policies, science, laws, patents and regulations of the biotechnology business. The book is said to be written to help all readers in understanding the concepts of biotechnology from the perspective of business. The fourth edition carries 49 figures, 74 boxes and 24 tables. Readers will get comprehensive idea on the ways of handling biotechnology companies with the help of Building Biotechnology by Yali Friedman.

One of the readers of Building Biotechnology says, "The need for a comprehensive guide to understanding the inner workings of corporate biotechnology is very acute, this book does much to fulfill the role."

The popularity of this book has reached great heights as now Building Biotechnology has been taken as an exclusive course text in a number of advanced programs on biotechnology including MBA programs of Boston, Tepper, UC Irvine university, MS/MBA program of Johns Hopkins Biotechnology and more.

The newly released Building Biotechnology is the fourth edition, which significantly appears to have updated business models, case laws and also added tables and more informative figures. The website buildingbiotechnology.com has listed the names of reference materials used to structure Yali Friedman's Building Biotechnology.

The website says, "Building Biotechnology enables seasoned business professionals and entrepreneurial scientists alike to understand the drivers of biotechnology businesses and apply their established skills for commercial success."

An informative and educative video-lecture series based on Building Biotechnology is available from the website buildingbiotechnology.com. The softcover and hardcover versions of this book are offered to customers through the Kindle store. Readers can understand the scope and definition of biotechnology from the point of view of business, with the help of the material presented in this book. It also appears to be the right choice to identify the needs for managing biotechnology companies.

To get more information about Building Biotechnology by Yali Friedman, visit http://www.buildingbiotechnology.com/

About Yali Friedman
Yali Friedman, the author of Building Biotechnology, has several years of experience in the field of biotechnology. He speaks and writes on topics like biotechnology entrepreneurship, technology based development of economy and more. He has been invited to different biotechnology forums organized by top establishments and countries across the world.

Media Contact

Yali Friedman, Ph.D.
thinkBiotech LLC
Address: 3909 Witmer Rd #416
Niagara Falls, NY 14305
Tel: 202-487-0089
Email: info@thinkbiotech.com
URL: http://www.buildingbiotechnology.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Building Biotechnology is now available; written by Yali Friedman, Ph.D., the 20-chapter book provides comprehensive coverage of the the biotechnology industry from business, legal, regulatory, policy, and scientific perspectives.

Niagara Falls, NY -- (SBWIRE) -- 12/02/2013 -- Explaining the scientific, business, legal, regulatory, and policy facets of biotechnology, Building Biotechnology, by Yali Friedman, Ph.D., is now available. This comprehensive 20-chapter, 388-page, primer covers biotechnology business, regulations, patents, law, policy, and science.

The book is structured to help readers understand biotechnology from a business perspective. It describes about how to start and manage biotech companies and meet their needs.

This most current release is the fourth edition of Building Biotechnology. Advanced biotechnology programs in dozens of many leading universities have used the book as a course guide. The new edition incorporates many features to aid those learning the industry. It has 49 figures, 24 informative tables, and 74 boxes to compliment the detailed and insightful text. Both hardcover and softcover versions are available, as is a Kindle version.

It was written by Yali Friedman, Ph.D., founder of thinkBiotech and a former instructor of biotechnology management at the National Institutes of Health (NIH) graduate school. Dr. Friedman also published the books Best Practices in Biotechnology Education, and Best Practices in Biotechnology Business Development and edits the global biotechnology innovation scorecard for Scientific American Worldview, proving exposure and experience with international biotechnology issues.. In addition, he is the chief editor and publisher of the Journal of Commercial Biotechnology. He has also taught biotechnology management and created the first blog on the business, named to Forbes "Best of the Web" list. A number of other achievements qualify him as an authority on the biotechnology industry.

Available for $74.95, Building Biotechnology covers the industry from a global business and scientific point of view. For more information, go to www.buildingbiotechnology.com.

About Yali Friedman, Ph.D.
Yali Friedman, Ph.D. is author of Building Biotechnology, chief editor and publisher of the Journal of Commercial Biotechnology. He is a former instructor at the National Institutes of Health (NIH) graduate school, where he taught biotechnology management for several years, and has been invited to participate in biotechnology industry development forums for international groups such as APEC and the Asian Productivity Organization, and for individual countries such as Japan, Canada, Germany, the Philippines, and Turkey.

Media Contact:

Yali Friedman, Ph.D.
thinkBiotech LLC
3909 Witmer Rd #416
Niagara Falls, NY 14305
202-487-0089
info@thinkbiotech.com
www.BuildingBiotechnology.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm